====== Tramadol (Ultram®) ======
^ Tramadol | {{ :neuro:opioids:tramadol_as_a_racemic_mixture.svg?200 |}} |
| Brand Names | Ultram®, ConZip® |
| Drug Class | [[neuro:opioids:start|Opioid]] (Weak μ-agonist, Dual Mechanism) |
| Primary Indication | Moderate Pain |
| Relative Potency | ~0.1× Morphine |
| Mechanism | Weak μ agonist + SNRI |
| Seizure Risk | Yes |
| Serotonin Syndrome Risk | Yes |
| Controlled Substance | Schedule IV |
| FDA Approval | 1995 |
===== Overview =====
Tramadol is a centrally acting analgesic with a dual mechanism of action:
* Weak μ-opioid receptor agonism
* Inhibition of serotonin and norepinephrine reuptake
It provides modest analgesia and carries unique risks not seen with traditional opioids, including seizures and serotonin syndrome.
----
===== Mechanism of Action =====
**Receptor Activity**
* Weak μ-opioid receptor agonist
**Monoamine Effects**
* Inhibits serotonin reuptake
* Inhibits norepinephrine reuptake
**Metabolism**
* CYP2D6 converts tramadol → O-desmethyltramadol (active metabolite with stronger μ activity)
Analgesic effect is partly dependent on CYP2D6 activity.
----
===== Indications =====
* Moderate acute pain
* Chronic musculoskeletal pain
* Neuropathic pain (limited evidence)
Not appropriate for severe pain requiring potent opioid therapy.
----
===== Contraindications =====
Absolute:
* Concomitant MAOI use
* Severe respiratory depression
* Acute intoxication with CNS depressants
Relative / Caution:
* Seizure disorders
* Concurrent SSRI/SNRI use
* Hepatic impairment
* Renal impairment
* CYP2D6 ultra-rapid metabolizers
----
===== Dosing =====
Immediate-Release:
* 50–100 mg every 4–6 hours
Maximum:
* 400 mg/day (lower in elderly)
Renal impairment:
* Dose adjustment required
Extended-release:
* Once daily dosing
----
===== Pharmacokinetics =====
Absorption:
* Oral
Metabolism:
* CYP2D6 → active metabolite
* CYP3A4 involvement
Half-life:
* ~6 hours
Elimination:
* Renal
CYP2D6 poor metabolizers → reduced analgesic effect
CYP2D6 ultra-rapid metabolizers → increased toxicity risk
----
===== Adverse Effects =====
Common:
* Nausea
* Dizziness
* Sedation
* Constipation
Serious:
* Seizures
* Serotonin syndrome
* Respiratory depression (less than full agonists)
* Physical dependence
Seizure risk increases with:
* High doses
* SSRIs/SNRIs
* TCAs
* Bupropion
----
===== Drug Interactions =====
Increased serotonin syndrome risk:
* SSRIs
* SNRIs
* MAOIs
* Linezolid
* St. John’s Wort
CYP2D6 inhibitors (↓ analgesia):
* Fluoxetine
* Paroxetine
CNS depressants:
* Benzodiazepines
* Alcohol
----
===== Monitoring =====
Clinical:
* Pain response
* Sedation
* Signs of serotonin toxicity
High-risk patients:
* History of seizures
* Polypharmacy
----
===== Clinical Pearls =====
* Weak μ agonist + SNRI mechanism.
* Analgesia depends partly on CYP2D6 activation.
* Higher seizure risk than other opioids.
* Risk of serotonin syndrome with SSRIs/SNRIs.
* Schedule IV (lower abuse potential than Schedule II opioids).
* Not appropriate for severe acute pain.
----
===== Toxicity =====
Overdose may present with:
* CNS depression
* Seizures
* Serotonin syndrome
* Respiratory depression
Naloxone may reverse respiratory depression but does NOT treat seizures.
See:
* [[neuro:opioids:naloxone|Naloxone]]
----
===== Comparison Within Class =====
Compared to [[neuro:opioids:morphine|Morphine]]:
* Much weaker
* Has serotonergic activity
Compared to [[neuro:opioids:tapentadol|Tapentadol]]:
* More serotonergic
* Higher seizure risk
Compared to [[neuro:opioids:codeine|Codeine]]:
* Similar potency
* More complex mechanism
----
===== Related =====
* [[neuro:opioids:start|Opioids]]
* [[neuro:opioids:tapentadol|Tapentadol]]
* [[neuro:opioids:morphine|Morphine]]
* [[neuro:opioids:naloxone|Naloxone]]